Shane Olwill
Corporate Officer/Principal chez PIERIS PHARMACEUTICALS, INC.
Fortune : 673 $ au 30/04/2024
Provenance du réseau au premier degré de Shane Olwill
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 30 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Shane Olwill via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| MORPHOSYS AG | Biotechnology | General Counsel Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
| VICORE PHARMA HOLDING AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| SANOFI | Miscellaneous Commercial Services | Corporate Officer/Principal Chief Operating Officer | |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| NEXTCURE, INC. | Pharmaceuticals: Major | Founder Director/Board Member | |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Chief Administrative Officer Chief Tech/Sci/R&D Officer | |
| JUNIPER PHARMACEUTICALS INC | Pharmaceuticals: Major | Chairman Comptroller/Controller/Auditor | |
| George Washington University Law School | College/University | Graduate Degree Graduate Degree | |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| University of Massachusetts | College/University | Undergraduate Degree Corporate Officer/Principal | |
Pieris Pharmaceuticals GmbH
 Pieris Pharmaceuticals GmbH BiotechnologyHealth Technology Part of Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH operates as a German biotechnology company. The private company is based in Hallbergmoos, Germany. The CEOs of the company are Hitto Kaufmann, Stephen S. Yoder. | Biotechnology | Chief Executive Officer Chief Executive Officer | |
| TRANSGENE | Biotechnology | Director/Board Member Director/Board Member | |
| University of Western Ontario | College/University | Undergraduate Degree | |
ONK Therapeutics Ltd.
 ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | Biotechnology | Director/Board Member | |
| University of Toronto | College/University | Doctorate Degree | |
Citigroup Alternative Investments LLC
 Citigroup Alternative Investments LLC Investment ManagersFinance Citigroup Alternative Investments LLC (CAI) is a SEC-registered asset management firm headquartered in New York City. The firm was founded in 2002 and is a wholly-owned subsidiary of Citigroup Investments, Inc., which is owned by Citigroup, Inc. (NYSE: C). CAI provides advisory services to private investment companies, such as private equity funds and funds of one or more private equity and real estate funds. The investors in the funds advised by the firm are institutional investors, funds of funds, high-net worth individuals and employees, and former employees of Citigroup, Inc. | Investment Managers | Portfolio Manager-Equities | |
Lombard Odier Asset Management (USA) Corp.
 Lombard Odier Asset Management (USA) Corp. Investment ManagersFinance Lombard Odier Asset Management (USA) Corp. (LOAM) is a SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 2000 and do-business-as Lombard Odier Investment Managers. The firm is a subsidiary of LO Holding SA and their ultimate parent is Switzerland-based Compagnie Lombard Odier SCmA. LOAM provides investment advisory services on a discretionary basis to private pooled investment vehicles (Funds) and investment advisory accounts. The investors in the Funds consist of endowments, foundations, insurance companies, high net-worth individuals, funds of funds, public and corporate pensions, and other sophisticated investors. | Investment Managers | Portfolio Manager-Equities | |
| FOGHORN THERAPEUTICS INC. | Biotechnology | Director of Finance/CFO | |
| PRIME MEDICINE, INC. | Biotechnology | Director of Finance/CFO | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
Polpharma Biologics Utrecht BV
 Polpharma Biologics Utrecht BV Miscellaneous Commercial ServicesCommercial Services Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands. | Miscellaneous Commercial Services | Director/Board Member | |
| Universität zu Köln | College/University | Doctorate Degree | |
| ARGENX SE | Pharmaceuticals: Other | Director/Board Member | |
Amakem NV
 Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Medical/Nursing Services | Director/Board Member | |
Roche Glycart AG
 Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
V-Bio Ventures BV
 V-Bio Ventures BV Investment ManagersFinance V-Bio Ventures BV is an Independent Venture Capital firm founded in 2015 by Christina Takke and Willem Broekaert. V-Bio Ventures BV is headquartered in Ghent. | Investment Managers | Founder | |
Precirix NV
 Precirix NV Pharmaceuticals: MajorHealth Technology Precirix NV develops and distributes radio-immunotherapeutic drugs for cancer patients. The company was founded on October 14, 2014 by Jens De Vos, Ludwig Camusot, Nick Devoogdt, Geert Raes, Tony Lahoutte and Matthias Dhuyvetter and is headquartered in Brussels, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Confo Therapeutics NV
 Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
V-Bio Management 1 BV
 V-Bio Management 1 BV Financial ConglomeratesFinance Part of V-Bio Ventures BV, V-Bio Management 1 BV functions as an investment holding Belgian company. The private company is based in Ghent, Belgium. | Financial Conglomerates | Director/Board Member | |
Syndesi Therapeutics SA
 Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
| Grove City College | College/University | Undergraduate Degree | |
| Technische Universität Darmstadt | College/University | Graduate Degree | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| University of Lancaster | College/University | Undergraduate Degree | |
| Perelman School of Medicine | College/University | Doctorate Degree | |
Immune Tolerance Institute, Inc.
 Immune Tolerance Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Part of The David H. Murdock Research Institute, Immune Tolerance Institute, Inc. provides integrated, state-of-the-art genomic, cellular, proteomic and bioinformatics technology platforms. The private company is based in Menlo Park, CA. Immune Tolerance Institute was acquired by The David H. Murdock Research Institute on June 09, 2011. | Miscellaneous Commercial Services | Chief Executive Officer | |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| Amherst College | College/University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 28 |
| Allemagne | 7 |
| Belgique | 7 |
| France | 3 |
| Canada | 3 |
Sectorielle
| Health Technology | 22 |
| Finance | 12 |
| Consumer Services | 11 |
| Commercial Services | 6 |
| Technology Services | 2 |
Opérationnelle
| Director/Board Member | 135 |
| Corporate Officer/Principal | 64 |
| Independent Dir/Board Member | 46 |
| Director of Finance/CFO | 29 |
| Chief Tech/Sci/R&D Officer | 22 |
Relations les plus connectées
| Insiders | |
|---|---|
| Chau Khuong | 38 |
| James Geraghty | 25 |
| Peter Kiener | 25 |
| Darlene Deptula-Hicks | 24 |
| Jean Bizzari | 24 |
| Julian Adams | 22 |
| Michael Richman | 16 |
| Matthew Sherman | 16 |
| Steven Prelack | 15 |
| Allan Reine | 14 |
| Christina Takke | 14 |
| Lance Thibault | 11 |
| Christopher Kiritsy | 10 |
| Ann J. Barbier | 9 |
| Richard Russo | 9 |
- Bourse
- Insiders
- Shane Olwill
- Connexions Sociétés
